Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.02 EUR | -0.73% | -1.83% | -22.67% |
08:49am | Bayer Menopause Drug Meets Key Goal in Late-Stage Trial | DJ |
08:36am | Bayer plans to apply for approval of drug to treat menopausal symptoms | DP |
Sales 2024 * | 47.31B 51.35B | Sales 2025 * | 48.53B 52.68B | Capitalization | 25.75B 27.95B |
---|---|---|---|---|---|
Net income 2024 * | 2.26B 2.46B | Net income 2025 * | 3.63B 3.94B | EV / Sales 2024 * | 1.24 x |
Net Debt 2024 * | 32.98B 35.8B | Net Debt 2025 * | 29.8B 32.35B | EV / Sales 2025 * | 1.14 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
7.35
x | Employees | 96,931 |
Yield 2024 * |
0.71% | Yield 2025 * |
3.07% | Free-Float | 99.97% |
Latest transcript on Bayer AG
1 day | -0.69% | ||
1 week | -2.26% | ||
Current month | -6.67% | ||
1 month | -8.37% | ||
3 months | -18.36% | ||
6 months | -46.11% | ||
Current year | -22.05% |
Managers | Title | Age | Since |
---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
Wolfgang Nickl
DFI | Director of Finance/CFO | 54 | 18-04-25 |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 68 | 21-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.77% | 70 M€ | -.--% | - | |
5.71% | 2 M€ | +13.56% | - | |
4.28% | 962 M€ | -.--% | - | |
4.10% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-19 | 26 | -0.80% | 230 755 |
24-03-18 | 26.22 | -0.08% | 2,958,874 |
24-03-15 | 26.24 | +0.81% | 9,539,161 |
24-03-14 | 26.02 | -1.27% | 3,608,300 |
24-03-13 | 26.36 | -0.49% | 3,351,866 |
Delayed Quote Xetra, March 18, 2024 at 12:35 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.05% | 28B | |
+30.83% | 687B | |
+30.96% | 595B | |
+0.01% | 378B | |
+15.18% | 316B | |
+11.39% | 308B | |
+0.78% | 211B | |
-6.09% | 208B | |
-2.92% | 203B | |
-3.72% | 157B |